NuVasive (NUVA) Receiving Somewhat Favorable Press Coverage, Study Finds
Media coverage about NuVasive (NASDAQ:NUVA) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NuVasive earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 36 out of 100, indicating that recent press coverage is unlikely to have an effect on the stock’s share price in the near term.
Here are some of the headlines that may have impacted Accern’s rankings:
- Innovation And Execution A Powerful Combination For NuVasive – Seeking Alpha (seekingalpha.com)
- Interesting NUVA Put And Call Options For August 18th (nasdaq.com)
- NuVasive, Inc. (NUVA) Given Average Rating of “Buy” by Analysts (americanbankingnews.com)
- Market Scope: Tracking Shares of NuVasive, Inc. (NASDAQ:NUVA) – Jonesboro Recorder (jonesbororecorder.com)
- Global Regenerative Medicines Market 2016 Industry Analysis & Forecast 2024 (medgadget.com)
Shares of NuVasive (NUVA) traded up 0.10% during midday trading on Thursday, reaching $76.91. 774,167 shares of the company were exchanged. The stock has a 50-day moving average price of $74.90 and a 200 day moving average price of $72.51. The company has a market capitalization of $3.90 billion, a P/E ratio of 80.70 and a beta of 1.23. NuVasive has a 52-week low of $56.70 and a 52-week high of $81.06.
NuVasive (NASDAQ:NUVA) last released its earnings results on Tuesday, April 25th. The medical device company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.01. The business had revenue of $249.86 million during the quarter, compared to the consensus estimate of $250.52 million. NuVasive had a net margin of 5.35% and a return on equity of 12.63%. The firm’s revenue for the quarter was up 16.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.34 earnings per share. Equities research analysts expect that NuVasive will post $2.01 EPS for the current fiscal year.
Several equities analysts have recently commented on NUVA shares. Cowen and Company restated an “outperform” rating and set a $85.00 price target on shares of NuVasive in a report on Monday, May 15th. Piper Jaffray Companies boosted their price target on shares of NuVasive from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Monday, June 12th. Zacks Investment Research upgraded shares of NuVasive from a “sell” rating to a “hold” rating in a report on Thursday, April 27th. TheStreet upgraded shares of NuVasive from a “c+” rating to a “b” rating in a report on Wednesday, May 3rd. Finally, Barclays PLC boosted their price target on shares of NuVasive from $80.00 to $82.00 and gave the company an “overweight” rating in a report on Monday, April 24th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $79.82.
NuVasive Company Profile
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.